Combination of Poly I: C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells

Cell Biology International

Volumn 35, Issue 8, 2011, Pages 803-810

  Shen, Peng ^a   Jiang, Tingwang ^b   Lu, Huiqi ^c   Han, Huanxing ^c   Luo, Rongcheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Clinical Immunology Department Changshu Medical Testing Center   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Arsenic trioxide; Hepatocellular carcinoma; Mitochondria; Poly I:C; Toll like receptor

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BID PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; CASPASE 3; CASPASE 8; CASPASE 9; INHIBITOR OF APOPTOSIS PROTEIN; INTERFERON INDUCING AGENT; ORGANOARSENIC DERIVATIVE; OXIDE; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; REACTIVE OXYGEN METABOLITE; TLR3 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 3;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; METHODOLOGY; MITOCHONDRION; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON INDUCERS; LIVER NEOPLASMS; MITOCHONDRIA; OXIDES; POLY I-C; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; TOLL-LIKE RECEPTOR 3;

EID: 81855162340     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20100739     Document Type: Article

References (67)

1. Adams M, Navabi H, Croston D, Coleman S, Tabi Z, Clayton A, et al. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 2005;23:2374-8.
2. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of doublestranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-8.
3. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
4. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res. 2003;9:2683-92.
5. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 2002;169:847-55.
6. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003;8:237-49.
7. Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo B, Dempsey PW, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 2010;70:2595-603.
8. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-ordeath switch. Nat Rev Cancer 2002;2:647-56.
9. Der SD, Yang YL, Weissmann C, Williams BR. A double-stranded RNAactivated protein kinase-dependent pathway mediating stressinduced apoptosis. Proc Natl Acad Sci USA 1997;94:3279-83.
10. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003;4:491-6.
11. Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 2004;172:6065-73.
12. Gogvadze V, Orrenius S. Mitochondrial regulation of apoptotic cell death. Chem Biol Interact 2006;163:4-14.
13. Harada K, Sato Y, Itatsu K, Isse K, Ikeda H, Yasoshima M, et al. Innate immune response to double-stranded RNA in biliary epithelial cells is associated with the pathogenesis of biliary atresia. Hepatology 2007;46:1146-54.
14. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006;6:644-58.
15. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci 2008;107:370-9.
16. Jackson JB, Nicholls DG. Methods for the determination of membrane potential in bioenergetic systems. Methods Enzymol 1986;127:557-77.
17. Jiang Q, Wei H, Tian Z. Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 2008;8:12.
18. Jiang XH, Wong BC, Yuen ST, Jiang SH, Cho CH, Lai KC, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001;91:173-9.
19. Johnson LV, Walsh ML, Bockus BJ, Chen LB. Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy. J Cell Biol 1981;88:526-35.
20. Juang SH, Wei SJ, Hung YM, Hsu CY, Yang DM, Liu KJ, et al. IFN-beta induces caspase-mediated apoptosis by disrupting mitochondria in human advanced stage colon cancer cell lines. J Interferon Cytokine Res 2004;24:231-43.
21. Kaiser WJ, Offermann MK. Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J Immunol 2005;174:4942-52.
22. Kalali BN, Kollisch G, Mages J, Muller T, Bauer S, Wagner H, et al. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-Imediated differential signaling. J Immunol 2008;181:2694-704.
23. Karlsson J, Ora I, Porn-Ares I, Pahlman S. Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin Cancer Res 2004;10:3179-88.
24. Khan AL, Heys SD, Eremin O. Synthetic polyribonucleotides: current role and potential use in oncological practice. Eur J Surg Oncol 1995;21:224-7.
25. Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 2007;100:1301-12.
26. Kito M, Akao Y, Ohishi N, Yagi K, Nozawa Y. Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2002;291:861-7.
27. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84.
28. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007;87:99-163.
29. Le UM, Yanasarn N, Lohr CV, Fischer KA, Cui Z. Tumor chemoimmunotherapy using gemcitabine and a synthetic dsRNA. Cancer Biol Ther 2008;7:440-7.
30. Lee HR, Cheong HJ, Kim SJ, Lee NS, Park HS, Won JH. Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF-kappaB in HCT116 colon cancer cells. Oncol Rep 2008;20:41- 7.
31. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4.
32. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999;1:461-6.
33. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501.
34. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-90.
35. Mori M, Yoneyama M, Ito T, Takahashi K, Inagaki F, Fujita T. Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation. J Biol Chem 2004;279:9698-702.
36. Morrison BH, Tang Z, Jacobs BS, Bauer JA, Lindner DJ. Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma. Biochem J 2005;385:595-603.
37. Noguchi R, Yoshiji H, Ikenaka Y, Kitade M, Kaji K, Yoshi J, et al. Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization. Int J Oncol 2008;32:193-9.
38. Nomi N, Kodama S, Suzuki M. Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway. Oncol Rep 2010;24:225-31.
39. Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008;29:1334-42.
40. Pennati M, Colella G, Folini M, Citti L, Daidone MG, Zaffaroni N. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 2002;109:285-6.
41. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
42. Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, Shoshan MC, et al. Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther 2009;8:160-70.
43. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
44. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176:4894-901.
45. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007;13:4565-74.
46. Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigenspecific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 2005;28:220-8.
47. Schroder M, Bowie AG. TLR3 in antiviral immunity: key player or bystander? Trends Immunol 2005;26:462-8.
48. Shankar SL, Mani S, O'Guin KN, Kandimalla ER, Agrawal S, Shafit-Zagardo B. Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem 2001;79:426-36.
49. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
50. Shi Y. Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci 2004;13:1979-87.
51. Siu KP, Chan JY, Fung KP. Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis. Life Sci 2002;71:275-85.
52. Sureda FX, Gabriel C, Comas J, Pallas M, Escubedo E, Camarasa J, et al. Evaluation of free radical production, mitochondrial membrane potential and cytoplasmic calcium in mammalian neurons by flow cytometry. Brain Res Brain Res Protoc 1999;4:280-7.
53. Tanaka N, Sato M, Lamphier MS, Nozawa H, Oda E, Noguchi S, et al. Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes Cells 1998;3:29-37.
54. Tattoli I, Carneiro LA, Jehanno M, Magalhaes JG, Shu Y, Philpott DJ, et al. NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-kappaB and JNK pathways by inducing reactive oxygen species production. EMBO Rep 2008;9:293-300.
55. Taura M, Fukuda R, Suico MA, Eguma A, Koga T, Shuto T, et al. TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. Cancer Sci 2010.
56. tenOever BR, Servant MJ, Grandvaux N, Lin R, Hiscott J. Recognition of the measles virus nucleocapsid as a mechanism of IRF-3 activation. J Virol 2002;76:3659-69.
57. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000;6:4957-64.
58. Verdijk RM, Mutis T, Esendam B, Kamp J, Melief CJ, Brand A, et al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 1999;163:57-61.
59. Wang J, Li L, Cang H, Shi G, Yi J. NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leukemia Res 2008;32:429-36.
60. Wang N, Liang Y, Devaraj S, Wang J, Lemon SM, Li K. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol 2009;83:9824-34.
61. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15.
62. Woo SH, Park IC, Park MJ, An S, Lee HC, Jin HO, et al. Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB activation. Int J Cancer 2004;112:596-606.
63. Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999;81:796-9.
64. Zhang R, Wang T, Li KN, Qin WW, Chen R, Wang K, et al. A survivin double point mutant has potent inhibitory effect on the growth of hepatocellular cancer cells. Cancer Biol Ther 2008;7:547-54.
65. Zhang T, Wang SS, Hong L, Wang XL, Qi QH. Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo. J Exp Clin Cancer Res 2003;22:61-8.
66. Zhang Y, Sun R, Liu B, Deng M, Zhang W, Li Y, et al. TLR3 activation inhibits nasopharyngeal carcinoma metastasis via downregulation of chemokine receptor CXCR4. Cancer Biol Ther 2009;8:1826-30.
67. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 2007;5:10.